Table 1.

Baseline patient characteristics.

Baseline Characteristic	Subset 1 (n=666)	Subset 2 (n=666)	Total (n=1,332)
Age, mean (SD)	37.8 (10.5)	38.2 (10.5)	38.0 (10.5)
Female, %	56.6	56.3	56.5
Region, %
East Asia	34.5	33.8	34.2
Mexico	40.8	43.5	42.2
The Middle East	22.5	19.7	21.1
Other region	2.1	3.0	2.6
Age at first symptoms of MDD, mean (SD)	33.6 (11.3)	33.8 (11.1)	33.7 (11.2)
BMI (kg/m2), mean (SD)	24.8 (4.3)	24.6 (4.3)	24.7 (4.3)
Living with a spouse/partner, %	65.9	64.6	65.2
Educational attainment, %
≤ Primary school	7.4	9.2	8.3
Secondary school/occupational programme	44.7	43.3	44.0
≥ University	47.9	47.6	47.8
Employment status, %
Full-time	55.9	55.3	55.6
Economically inactive	27.0	25.1	26.1
Unemployed/part-time	17.1	19.7	18.4
CGI-S score at baseline, mean (SD)	4.5 (0.7)	4.5 (0.7)	4.5 (0.7)
QIDS-SR16 score at baseline, mean (SD)	14.2 (4.9)	14.5 (4.8)	14.4 (4.8)
EQ-VAS score at baseline, mean (SD)	43.6 (26.1)	42.7 (25.7)	43.2 (25.9)
EQ-5D index at baseline, mean (SD)	0.48 (0.33)	0.46 (0.33)	0.47 (0.33)
SSI-pain score at baseline, mean (SD)	14.5 (5.1)	14.3 (5.1)	14.4 (5.1)
Had MDD episodes in the 24 months prior to baseline, %	65.8	65.6	65.7
Had been hospitalised for MDD in the 24 months prior to baseline, %	5.3	5.4	5.3
Initiating treatment with SSRIs (vs. duloxetine), %	58.9	57.7	58.3
Having significant co-morbidities, %	24.3	26.8	25.6
Painful physical symptoms, %	53.0	49.9	51.5

Abbreviations: BMI, Body Mass Index; CGI-S, Clinical Global Impressions of Severity; EQ-VAS, EuroQoL-Visual Analogue Scale; EQ-5D, EuroQoL-5 Dimensions; MDD, Major Depressive Disorder; QIDS-SR16, 16-item Quick Inventory of Depressive Symptomatology Self-Report; SD, Standard Deviation; SSI-pain, Somatic Symptom Inventory; SSRI, Selective Serotonin Reuptake Inhibitor